It Seems Audentes Therapeutics Incorporated (NASDAQ:BOLD) Will Go Down. Just Reported More Shorted Shares

January 13, 2018 - By reb123z

 It Seems Audentes Therapeutics Incorporated (NASDAQ:BOLD) Will Go Down. Just Reported More Shorted Shares

The stock of Audentes Therapeutics Incorporated (NASDAQ:BOLD) registered an increase of 5.5% in short interest. BOLD’s total short interest was 825,000 shares in January as published by FINRA. Its up 5.5% from 782,000 shares, reported previously. With 255,400 shares average volume, it will take short sellers 3 days to cover their BOLD’s short positions. The short interest to Audentes Therapeutics Incorporated’s float is 8.89%.

The stock increased 3.59% or $1.3 during the last trading session, reaching $37.47. About 344,682 shares traded or 18.21% up from the average. Audentes Therapeutics, Inc. (NASDAQ:BOLD) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company has market cap of $1.12 billion. The firm is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It currently has negative earnings. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar.

More notable recent Audentes Therapeutics, Inc. (NASDAQ:BOLD) news were published by: Prnewswire.com which released: “Audentes Therapeutics Announces FDA Clearance of Investigational New Drug …” on April 03, 2017, also Bizjournals.com with their article: “This ‘bold’ IPO will say a lot about Wall Street, biotech and gene therapy (Video)” published on July 20, 2016, Bizjournals.com published: “Gene therapy company Audentes shoots for $86M IPO” on January 04, 2016. More interesting news about Audentes Therapeutics, Inc. (NASDAQ:BOLD) were released by: Marketwatch.com and their article: “Audentes Therapeutics Inc.” published on November 10, 2011 as well as Prnewswire.com‘s news article titled: “Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior …” with publication date: May 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.